Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Peter M BecherBenedikt SchrageGiulia FerranniniLina BensonJaved ButlerJuan Jesus CarreroFrancesco CosentinoUlf DahlströmLinda MellbinGiuseppe M C RosanoGianfranco SinagraDavide StolfoLars H LundGianluigi SavaresePublished in: European journal of heart failure (2021)
In a contemporary HF cohort with T2DM, SGLT2i use increased over time, was more common with specialist care, younger age, ischaemic heart disease, and preserved renal function, and was associated with lower mortality and morbidity.
Keyphrases
- palliative care
- heart failure
- glycemic control
- acute heart failure
- healthcare
- electronic health record
- cardiovascular events
- quality improvement
- pulmonary hypertension
- big data
- left ventricular
- type diabetes
- risk factors
- atrial fibrillation
- cardiac resynchronization therapy
- metabolic syndrome
- machine learning
- pain management
- insulin resistance
- chronic pain
- skeletal muscle